Navigation Links
Sofie Biosciences Raises $2M to Support Development of Diagnostic Imaging Agents and Devices
Date:12/8/2010

CULVER CITY, Calif., Dec. 8, 2010 /PRNewswire/ -- Sofie Biosciences, a developer of agents and devices for the molecular imaging of disease, announced today the closing of an additional $2 million from new and existing investors. Funds will be used for the development of new PET imaging agents and for enhancements to their PET imaging systems and chemistry units. The round includes the first institutional and large corporate financing to the firm including investment by the Cycad Group.

(Logo: http://photos.prnewswire.com/prnh/20101208/LA13841LOGO)

"This investment represents an important step towards achieving our goal of rapidly commercializing new PET technologies and imaging agents in an effort to make PET more widely accessible to more physicians and scientists," said Patrick Phelps, President and CEO of Sofie.

Sofie Biosciences is developing novel molecular imaging agents to enable earlier and more accurate diagnosis, treatment selection, and therapeutic monitoring of major medical disorders. Sofie is combining new PET imaging agents with innovative imaging systems to provide researchers and physicians with tools to better investigate the biology of disease.

Sofie's founders are leading scientists and clinicians in the field. They include the inventor of the PET scanner and Chairman of the Department of Molecular & Medical Pharmacology at UCLA, Dr. Michael Phelps; the Director of The Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, Dr. Owen Witte; the Director of The Ahmanson Biological Imaging Division at UCLA, Dr. Johannes Czernin; and the Director of the NCI Nanosystems Cancer Center at Caltech, Dr. James Heath.

Sofie has obtained an exclusive license from the University of California to a family of PET molecular imaging agents collectively referred to as FAC. FAC has been shown in preclinical animal research and early patient studies to have promise as a whole-body noninvasive means of determining whether a cancer patient will respond to a class of therapeutics known as nucleoside prodrugs. At present, this class of drugs is widely used in patient care, and is the subject of a large number of current clinical trials.  FAC also shows early indications that it will be the first means available to image the activation of the immune system and the organ distribution of immune response to diseases, immunotherapies, infections and organ rejection over time.

Rather than focusing its initial commercialization efforts on the expensive clinical development of imaging probes, Sofie has made it a priority to first make PET imaging technology, like its bench-top small animal PET scanner, GENISYS, and the preclinical use of its FAC agent, more widely accessible to researchers.  This will lead to further utilization of PET, increased adoption of Sofie's agents into cutting edge research, and eventually in the clinic, which will further fuel the adoption of this potentially life saving medical imaging technology.

For additional information on Sofie Biosciences, please visit www.sofiebio.com or contact Mr. Patrick Phelps at 310.242.6794 or patrick.phelps@sofiebio.com.


'/>"/>
SOURCE Sofie Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  Drug diversion is a ... and deadly overdoses. A new oral fluid monitoring ... www.cordantsolutions.com , reports more detailed and actionable information ... potentially improve therapy adherence, patient safety, and help ... Comprehensive Oral fluid Rx Evaluation (CORE) system is ...
(Date:3/23/2017)... 2017  The goal of the pilot is ... track prescription drugs as they are distributed in ... requirements from US FDA to better protect consumers by ... Blockchain startup Chronicled, which links the ... blockchain technology and recently raised $6.25M, and the LinkLab, ...
(Date:3/23/2017)... LONDON , March 23, 2017 ... efficacy from the TACTI-mel trial of IMP321 in combination ... in the first (1mg/kg) cohort experiencing a complete response. ... final cohort is expected to be fully recruited by ... of the AIPAC breast cancer study are expected mid-year ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ Through Social ... devotional journal chronicling the writer’s path toward true communion with God. “Finding Christ ... #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a follower of ...
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Boulder, CO (PRWEB) , ... March 23, 2017 , ... ... higher bar for entry into teacher preparation programs. The NCTQ report suggests, based on ... boosting entry requirements would significantly improve teacher quality in the U.S. It argues that ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... health services to their communities, 16 more public health departments have been awarded ... decisions bring another 4.5 million people into the expanding network of communities across ...
Breaking Medicine News(10 mins):